Subscribe
marianvejcik-istockphoto-com-gavel-uk-
27 October 2017Big Pharma

Teva suffers defeat as Copaxone claims invalidated

The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York